MATTR
18.6.2021 07:02:10 CEST | Business Wire | Press release
MATTR, a provider of verifiable data and digital trust solutions, today announced the availability of the MATTR VII platform on Auth0 Marketplace , a catalog of trusted technology integrations to extend the functionality of Auth0’s identity management platform.
The MATTR VII platform provides an integrated approach to decentralised identity and data ownership. It decouples a user’s identity from their service providers, delivering significant benefits to users and giving builders and developers all the tools they need to create a whole new universe of decentralized products and applications. MATTR VII is composable and configurable to fit developers’ needs, whether it’s a well-established business with legacy systems or a start-up looking to build the next best thing in digital privacy.
“MATTR is pleased to partner with Auth0, and welcomes Auth0’s recognition that MATTR’s approach to decentralised identity and data ownership can provide a powerful way to extend and enhance investment already made in authentication and identity solutions,” said Claire Barber, CEO at MATTR. “We’re looking forward to seeing the innovation and value that these new tools are used to create.”
“It has been really exciting to work with MATTR on a newly-built partner integration for the Auth0 Marketplace . This best-in-class solution adds an integral layer to our platform that provides our customers with greater choice and flexibility,” said Cassio Sampaio, SVP of Product at Auth0. “After speaking with many customers, we have identified the types of integrations that matter to them, and we are so thrilled to have MATTR as a vetted and valuable vendor in Auth0 Marketplace.”
With MATTR and Auth0, organizations can act as authoritative issuers of verifiable credentials, leveraging their existing Auth0 accounts and OpenID Connect flows to issue portable credentials to employees, customers or partners.
MATTR VII with the OIDC Bridge Extension complements Auth0 Extensible Identity, and the ease in which customers can seamlessly integrate adjacent technologies to facilitate the successful execution of larger projects such as digital transformation, threat detection, compliance, and customer conversion.
All partner integrations are thoroughly vetted and verified for security and functionality by Auth0, and are easily discoverable for customers. Partners can participate in the growing demand for digital identity solutions and increase their visibility as part of the Auth0 Marketplace, and can learn more here: https://auth0.com/partners .
About Auth0
Auth0’s modern approach to identity enables organizations to provide secure access to any application, for any user. The Auth0 platform is a highly customizable identity operating system that is as simple as development teams want and as flexible as they need. Safeguarding billions of login transactions each month, Auth0 delivers convenience, privacy, and security so customers can focus on innovation. For more information, visit https://auth0.com
.
About MATTR
MATTR is building a web of trust, restoring confidence in digital interactions through an integrated approach to decentralised identity and data ownership. The MATTR VII platform provides the building blocks to address the historically difficult challenges of digital security, privacy and data verification. Our products are simple, accessible and easy to use, with pre-built extensions that make it easy to plug the platform into existing application stacks. MATTR is committed to open standards, and works with organisations such as W3C, DIF and OIDF.
For more information visit https://mattr.global or follow @MattrGlobal on Twitter .
View source version on businesswire.com: https://www.businesswire.com/news/home/20210617005938/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
Samsung Biologics Strike: Labor Union Warns of CDMO Supply Chain Risks Following Overwhelming Vote30.3.2026 11:52:00 CEST | Press release
Union members overwhelmingly approve strike action with 95.52% voting in favor on a 95.38% turnout, clearing the final legal hurdle after mediation ceased.Union emphasizes this is a fight against structural corporate governance issues, citing unresolved allegations concerning unfair labor practices and ESG compliance risks.Management adhered to a group-level wage guideline rather than bargaining on the basis of Samsung Biologics' own performance, exposing a lack of independent bargaining authority. The Samsung Biologics Labor Union (President: Jaesung Park), representing approximately 75% of the company's total employees, announced today that its members have overwhelmingly voted in favor of a strike, with 95.52% voting in favor on a 95.38% turnout during a voting period from March 24 to March 29. Following the Incheon Regional Labor Relations Commission's decision to cease mediation, the union has now secured the legal mandate to strike. The union stressed that this strike is not mere
The Premier Jumping League (PJL) Launches with a Record-Breaking $300 Million Guaranteed Prize Pot, Defining a New Era for Showjumping30.3.2026 11:00:00 CEST | Press release
The PJL empowers riders to compete as full-time professional athletes while working towards a sustainable economic model for the sport. Backed by McCourt Global and shaped by a leadership team with decades of experience in equestrian competition, sport, and entertainment, the PJL sets a new, sustainable, and globally relevant standard for elite jumping. Sixteen teams will compete across fourteen iconic international venues throughout Europe, North America, and the Middle East when the inaugural season opens in March 2027. The Premier Jumping League (PJL) launches with a record-breaking $300 million guaranteed prize pot, defining a new era for showjumping. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330990938/en/ Photography credits: Daniel Benson for The Premier Jumping League/ Wieden+Kennedy London Backed by McCourt Global and its Executive Chairman, Frank McCourt, the PJL is a groundbreaking global competition that e
Dompé Announces First Patient Enrolled in New Study of Intranasal NGF in Cerebral Palsy30.3.2026 11:00:00 CEST | Press release
Cerebral Palsy (CP) refers to a group of permanent disorders in the development of movement and posture, which causes activity limitations, and is attributed to non-progressive disturbances that occurred in the developing fetal or infant brain.1 Nerve growth factor (NGF) is a naturally-occurring protein that supports damaged nerve cells and improves nervous system signaling, Dompé is investigating whether intranasal NGF has the potential to improve movement and neurodevelopment and address underlying brain damage in people with CP. Dompé’s intranasal NGF platform builds on the Nobel Prize-winning discovery of neurobiologist Professor Rita Levi-Montalcini and biochemist Dr. Stanley Cohen. Dompé, a leading biopharmaceutical company with operations in Italy and in the U.S., announced that the first patient has been enrolled at the Agostino Gemelli IRCCS University Hospital in Rome, Italy, in a Phase 2 investigational study of an intranasal form of Nerve Growth Factor (NGF) (Cenegermin-bkb
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom